| Not Yet Recruiting | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimuma NCT07511036 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Ex NCT07444606 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors NCT07518043 | Shanghai Henlius Biotech | Phase 1 |
| Not Yet Recruiting | A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Partici NCT07475572 | Alvotech Swiss AG | Phase 1 |
| Not Yet Recruiting | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Par NCT07476326 | Biocon Biologics UK PLC | Phase 1 |
| Not Yet Recruiting | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanom NCT07529080 | University of Michigan Rogel Cancer Center | N/A |
| Enrolling By Invitation | Natural History Study of Early Life Exposures in Agriculture (ELEA) NCT07328516 | National Cancer Institute (NCI) | — |
| Not Yet Recruiting | Clinical Genetics Branch Eligibility Screening Survey NCT07005297 | National Cancer Institute (NCI) | — |
| Not Yet Recruiting | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma NCT07517653 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and In NCT07524114 | University Health Network, Toronto | — |
| Not Yet Recruiting | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study NCT07389525 | Indiana University | EARLY_Phase 1 |
| Not Yet Recruiting | Intratumoral N17350 in Advanced Solid Tumors NCT07339176 | Onchilles Pharma Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Mel NCT07437300 | University Hospital, Grenoble | — |
| Recruiting | A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out W NCT07224425 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization NCT05264974 | University of Florida | Phase 1 |
| Recruiting | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma NCT06365619 | University of Utah | Phase 2 |
| Not Yet Recruiting | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stres NCT07102212 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors NCT07161310 | Goethe University | N/A |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation NCT05275374 | Xynomic Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | Promoting Immunotherapy Efficacy With Low-Dose Liver RT NCT07225036 | Jordan Kharofa | N/A |
| Recruiting | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348 | Replimune, Inc. | — |
| Recruiting | Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for t NCT07379138 | Mayo Clinic | N/A |
| Recruiting | The Florida ASCENT Study NCT07042243 | University of Florida | N/A |
| Recruiting | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma NCT06961357 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 NCT05770544 | Cancer Research UK | Phase 2 / Phase 3 |
| Not Yet Recruiting | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile NCT06897735 | Petrov, Andrey | Phase 1 |
| Recruiting | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 | Diwakar Davar | Phase 2 |
| Not Yet Recruiting | Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melano NCT07040280 | Eastern Cooperative Oncology Group | Phase 2 |
| Not Yet Recruiting | A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melan NCT07028008 | Samsung Medical Center | N/A |
| Recruiting | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda NCT07160335 | Shanghai Henlius Biotech | Phase 1 |
| Recruiting | VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591 | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Recruiting | Contrast-enhanced Ultrasound for Sentinel Node Detection NCT07310758 | The Netherlands Cancer Institute | Phase 2 / Phase 3 |
| Recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496 | University of Arizona | Phase 1 / Phase 2 |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Recruiting | NG2 and DLL3 CAR-T Cells Targeting Melanoma NCT07193966 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Combination Immunotherapy Targeting Melanoma NCT06739226 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | IDOV-Immune for Advanced Solid Tumors NCT06910657 | ViroMissile, Inc. | Phase 1 |
| Recruiting | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Me NCT06712927 | Stanford University | Phase 2 |
| Recruiting | MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. NCT07092670 | Intergruppo Melanoma Italiano | — |
| Recruiting | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) i NCT06398418 | Rise Therapeutics LLC | Phase 1 |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of NCT06753136 | Istituto Oncologico Veneto IRCCS | N/A |
| Recruiting | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 | Natera, Inc. | — |
| Recruiting | Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients NCT06906822 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Recruiting | An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Completed | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ip NCT07091695 | Bristol-Myers Squibb | — |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Terminated | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors NCT06799533 | Pfizer | Phase 1 |
| Not Yet Recruiting | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy NCT06683755 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma NCT06508827 | Indiana University | Phase 2 |
| Enrolling By Invitation | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Trea NCT06848088 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Evaluation of Hypoxia in Primary Melanoma NCT06831071 | Yana Najjar | — |
| Recruiting | LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanom NCT06623461 | Canadian Cancer Trials Group | Phase 2 |
| Not Yet Recruiting | Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial NCT05004792 | Herlev Hospital | N/A |
| Recruiting | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991 | Inge Marie Svane | Phase 1 |
| Not Yet Recruiting | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST NCT06756295 | Fengming Kong | EARLY_Phase 1 |
| Active Not Recruiting | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With U NCT06797297 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi NCT06599619 | John Kirkwood | — |
| Recruiting | In Vivo Liquid Biopsy of Melanoma (Cytophone) NCT06488365 | Cytoastra | N/A |
| Terminated | YASU Research Registry: For Young Adults With Cancer NCT06275854 | Young Adult Survivors United | — |
| Not Yet Recruiting | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis NCT06785974 | Erasmus Medical Center | Phase 4 |
| Recruiting | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology C NCT06418204 | Wake Forest University Health Sciences | — |
| Recruiting | WoW - Single- vs Two-staged Excisions of Thin Melanoma NCT06363591 | Vastra Gotaland Region | N/A |
| Recruiting | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours NCT06708663 | Hangzhou Hanx Biopharmaceuticals, Ltd. | Phase 1 / Phase 2 |
| Recruiting | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL NCT06630611 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Recruiting | Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail NCT06861023 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma NCT06771544 | University of California, Irvine | Phase 2 |
| Recruiting | A Study of GC101 TIL in Advanced Melanoma NCT06703398 | Shanghai Juncell Therapeutics | Phase 2 |
| Terminated | Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB89 NCT06587451 | Sandoz | Phase 3 |
| Active Not Recruiting | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable NCT06784648 | BioInvent International AB | Phase 1 / Phase 2 |
| Not Yet Recruiting | LATe TreatmENT Related Toxicity in Melanoma (LATENT) NCT06414343 | Royal Marsden NHS Foundation Trust | — |
| Terminated | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer NCT06580938 | Pfizer | Phase 1 |
| Recruiting | Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management NCT06627595 | University Hospital, Montpellier | — |
| Not Yet Recruiting | Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma NCT06566404 | European Institute of Oncology | — |
| Completed | Sun Protection and Tanning Awareness in Rural Schools NCT06694571 | University of Utah | N/A |
| Recruiting | Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App NCT06675643 | Mayo Clinic | — |
| Completed | Head and Neck Melanoma; Access to Staging and Surgical Treatment NCT05900102 | Hull University Teaching Hospitals NHS Trust | — |
| Recruiting | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemipl NCT06413680 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participant NCT06190951 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Res NCT06548789 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors NCT06596915 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Recruiting | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metast NCT06246916 | Regeneron Pharmaceuticals | Phase 3 |
| Unknown | iToBoS: Clinical Data Acquisition Study NCT05075356 | The University of Queensland | N/A |
| Active Not Recruiting | A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients NCT06540391 | Microbiotica Ltd | Phase 1 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors NCT06500091 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Suspended | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma NCT05756556 | ImmVira Pharma Co. Ltd | Phase 2 |
| Active Not Recruiting | Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 NCT06384417 | Milton S. Hershey Medical Center | N/A |
| Not Yet Recruiting | Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy NCT06470880 | The Christie NHS Foundation Trust | Phase 2 |
| Not Yet Recruiting | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma NCT06424626 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma NCT06295159 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Not Yet Recruiting | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With NCT06327698 | Hunan Cancer Hospital | Phase 2 |
| Active Not Recruiting | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® i NCT06153238 | Sandoz | Phase 1 |
| Terminated | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M NCT06287463 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Terminated | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combi NCT06448364 | Pfizer | Phase 1 |
| Active Not Recruiting | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) NCT05973487 | TScan Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors NCT06326411 | Nested Therapeutics, Inc | Phase 1 |
| Recruiting | A Study of IBI363 in Subjects with Advanced Solid Malignancies NCT06281678 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | BostonGene and Exigent Genomic INsight Study NCT06272864 | BostonGene | — |
| Recruiting | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours NCT06305247 | Ipsen | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants NCT06566092 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Completed | Etude rétrospective Monocentrique MATRIX NCT06415929 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma NCT06727630 | Zhuhai Yufan Biotechnologies Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma NCT06240143 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis NCT06216938 | Yana Najjar | EARLY_Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma C NCT06254196 | Regina Elena Cancer Institute | N/A |
| Recruiting | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Daiichi Sankyo | Phase 2 |
| Terminated | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors NCT06285097 | Pfizer | Phase 1 |
| Active Not Recruiting | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy NCT06598137 | LMU Klinikum | — |
| Active Not Recruiting | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 G NCT06237881 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients NCT06199713 | University of Wisconsin, Madison | — |
| Not Yet Recruiting | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenabl NCT06212388 | Xijing Hospital | EARLY_Phase 1 |
| Recruiting | Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Pat NCT06154668 | University Hospital, Grenoble | — |
| Completed | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptabil NCT06168825 | Inova Health Care Services | — |
| Active Not Recruiting | Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation NCT06146920 | Massachusetts General Hospital | N/A |
| Withdrawn | A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma NCT05561491 | Targovax Oy | Phase 2 |
| Recruiting | Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and NCT06680323 | University Hospital Tuebingen | — |
| Unknown | Community Based Strategies for Early Detection of Melanoma NCT04799106 | Cedars-Sinai Medical Center | — |
| Active Not Recruiting | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase NCT06099782 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable NCT05280314 | IO Biotech | Phase 2 |
| Recruiting | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogre NCT05830058 | City of Hope Medical Center | Phase 2 |
| Terminated | IMM60 and Pembrolizumab in Melanoma and NSCLC NCT05709821 | iOx Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of GC101 TIL in Advanced Melanoma (BZ) NCT06120712 | Shanghai Juncell Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Ni NCT06101134 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106 | Shanghai Kechow Pharma, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Mela NCT06054555 | Amgen | Phase 3 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Completed | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy NCT06495008 | University Medical Center Groningen | — |
| Recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Canc NCT05770102 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613 | Obsidian Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of IBI363 in Subjects With Advanced Melanoma NCT06081920 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors NCT05483400 | University Medical Center Groningen | Phase 2 |
| Terminated | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies NCT06052852 | Bolt Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations NCT06229340 | N.N. Petrov National Medical Research Center of Oncology | Phase 2 |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Completed | Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy NCT05707286 | Indiana University | — |
| Recruiting | Excision of Lymph Node Trial (EXCILYNT) (Mel69) NCT05839912 | Craig L Slingluff, Jr | N/A |
| Recruiting | Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma NCT07404605 | Institute of Oncology Ljubljana | N/A |
| Enrolling By Invitation | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 NCT05212103 | Turku University Hospital | — |
| Terminated | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors NCT05909995 | Incyte Corporation | Phase 1 |
| Recruiting | Perioperative Treatment With Tranexamic Acid in Melanoma NCT05899465 | University of Aarhus | Phase 3 |
| Recruiting | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma NCT05983237 | Jun Guo | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Mel NCT06163170 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Survival Monitoring in Russian Cancer Registries NCT06043947 | N.N. Petrov National Medical Research Center of Oncology | — |
| Completed | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma NCT05907122 | Amgen | Phase 3 |
| Suspended | The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) NCT04866810 | National Cancer Institute (NCI) | N/A |
| Recruiting | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105 | Innolake Biopharm | Phase 1 / Phase 2 |
| Recruiting | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue NCT05837767 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) NCT05933577 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Active Not Recruiting | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunother NCT05703269 | Wake Forest University Health Sciences | N/A |
| Recruiting | Metabolic Phenotypes in Melanoma NCT05570227 | Peter MacCallum Cancer Centre, Australia | N/A |
| Recruiting | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors NCT05961111 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Completed | TRAQinform Assessment of Immunotherapy Response NCT05819255 | AIQ Solutions | — |
| Active Not Recruiting | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid T NCT05902520 | AgonOx, Inc. | Phase 1 |
| Terminated | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab NCT05926960 | Pfizer | Phase 2 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117 | MacroGenics | Phase 2 |
| Active Not Recruiting | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma NCT05912244 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors NCT05867303 | RemeGen Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer NCT05496192 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE NCT07403630 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Seque NCT06028724 | Centro di Riferimento Oncologico - Aviano | — |
| Recruiting | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. NCT05878964 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Enrolling By Invitation | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenviron NCT05600933 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05789069 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma NCT05823246 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers a NCT05819827 | Mayo Clinic | — |
| Unknown | 'Cancer Patients Better Life Experience' NCT05827289 | The Netherlands Cancer Institute | N/A |
| Recruiting | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid T NCT05746897 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Recruiting | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy NCT06666634 | The Netherlands Cancer Institute | N/A |
| Recruiting | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants W NCT05727904 | Iovance Biotherapeutics, Inc. | Phase 3 |
| Unknown | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma NCT05723432 | Shanghai Kanda Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | OH2 Injection in Melanoma NCT05868707 | Binhui Biopharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After An NCT05222932 | TILT Biotherapeutics Ltd. | Phase 1 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors NCT05373823 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic NCT05625399 | Bristol-Myers Squibb | Phase 3 |
| Unknown | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (V NCT05708950 | Kineta Inc. | Phase 1 / Phase 2 |
| Recruiting | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Posi NCT05768178 | Cancer Research UK | Phase 2 / Phase 3 |
| Terminated | CD8 Minibody Repeatability Study NCT05744128 | ImaginAb, Inc. | Phase 2 |
| Unknown | AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy NCT06080711 | Karolinska University Hospital | N/A |
| Recruiting | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patient NCT05428007 | NYU Langone Health | Phase 2 |
| Completed | Mentored Community Gardening for Individuals With Skin Cancer NCT05648604 | University of Arizona | N/A |
| Active Not Recruiting | Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL) NCT04866680 | Institut de Cancérologie de Lorraine | N/A |
| Completed | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma NCT05665595 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing NCT05608291 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combi NCT05661955 | BeiGene | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 | Asher Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma NCT05867004 | Institut Claudius Regaud | — |
| Terminated | A Study to Investigate LYL845 in Adults With Solid Tumors NCT05573035 | Lyell Immunopharma, Inc. | Phase 1 |
| Completed | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combi NCT05668585 | C4 Therapeutics, Inc. | Phase 1 |
| Recruiting | Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma NCT05429138 | Assistance Publique Hopitaux De Marseille | — |
| Recruiting | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases NCT05522660 | ETOP IBCSG Partners Foundation | Phase 3 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With A NCT05538130 | Pfizer | Phase 1 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study NCT05645510 | University of Alberta | — |
| Recruiting | Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS NCT05180942 | Monash University | — |
| Completed | Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors NCT06046144 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Recruiting | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or D NCT05607095 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melan NCT05062096 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma NCT05478473 | Peking University Cancer Hospital & Institute | N/A |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Terminated | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa- NCT05393713 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma NCT05539118 | Xijing Hospital | Phase 1 / Phase 2 |
| Recruiting | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma NCT05512481 | Peking University Cancer Hospital & Institute | Phase 2 |
| Active Not Recruiting | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazol NCT05470283 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma NCT04971499 | April Salama, M.D. | Phase 1 / Phase 2 |
| Unknown | The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma NCT05645484 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Active Not Recruiting | Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malig NCT05520294 | University of Colorado, Denver | — |
| Unknown | Immunological Variables Associated to ICI Toxicity in Cancer Patients NCT05429866 | Jules Bordet Institute | Phase 2 |
| Unknown | Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patient NCT05145829 | Zuyderland Medisch Centrum | N/A |
| Completed | The Impact of a Prevention Program on Sun Risks in Primary School in Tropical French Region NCT05367180 | Centre Hospitalier Universitaire de la Réunion | N/A |
| Completed | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations NCT05810740 | Pierre Fabre Medicament | Phase 1 |
| Recruiting | Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients NCT05029791 | Hospices Civils de Lyon | N/A |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Completed | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Me NCT05419388 | Hoffmann-La Roche | Phase 2 |
| Active Not Recruiting | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance NCT05061134 | AstraZeneca | Phase 2 |
| Terminated | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During S NCT05457842 | Astellas Pharma Inc | Phase 2 |
| Unknown | Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanom NCT05451407 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Video Education With Result Dependent dIsclosure NCT05225428 | Dana-Farber Cancer Institute | N/A |
| Active Not Recruiting | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors NCT05180799 | BioAtla, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy NCT05732805 | Biocad | Phase 3 |
| Completed | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Com NCT05297565 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | A Study of Tumor Imaging With Multispectral Optoacoustic Tomography NCT05488483 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease NCT05229614 | CNAO National Center of Oncological Hadrontherapy | Phase 2 |
| Recruiting | Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) NCT05196087 | University Health Network, Toronto | — |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Unknown | Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis NCT05406466 | Fudan University | Phase 2 |
| Active Not Recruiting | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patien NCT05352672 | Regeneron Pharmaceuticals | Phase 3 |
| Unknown | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. NCT06321640 | European Institute of Oncology | — |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | A Study of TRK-950 in Patients With Advanced Solid Tumors NCT05423262 | Toray Industries, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Al NCT05355701 | Pfizer | Phase 1 |
| Recruiting | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) NCT05403177 | University Health Network, Toronto | — |
| Active Not Recruiting | VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer NCT05592639 | University College, London | N/A |
| Recruiting | MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Ca NCT05620290 | Sunnybrook Health Sciences Centre | Phase 1 |
| Recruiting | Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry NCT05673681 | Fundación Academia Española de Dermatología | — |
| Terminated | Long-Term Follow-Up Study of Patients Receiving ATL001 NCT04785365 | Achilles Therapeutics UK Limited | Phase 2 |
| Recruiting | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478 | Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 1 |
| Unknown | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers NCT04913025 | University College, London | Phase 2 |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT05311618 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Completed | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NR NCT05340621 | OnKure, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. NCT05270044 | Pierre Fabre Medicament | Phase 3 |
| Terminated | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors NCT07121829 | Day One Biopharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 NCT05354102 | Biomica Ltd. | Phase 1 |
| Recruiting | High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies NCT05053555 | M.D. Anderson Cancer Center | N/A |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Terminated | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors NCT05229601 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidat NCT04751396 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors NCT05121545 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Unknown | ERK Inhibitor JSI-1187 in Advanced Solid Tumors NCT06239623 | JS InnoPharm, LLC | Phase 1 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o NCT05215574 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma NCT05130177 | Diwakar Davar | Phase 2 |
| Terminated | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors NCT05169437 | Tempus AI | Phase 2 |
| Active Not Recruiting | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma NCT05289193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT05621837 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Active Not Recruiting | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05238883 | HiFiBiO Therapeutics | Phase 1 |
| Terminated | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma NCT05234437 | QBiotics Group Limited | Phase 2 |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Active Not Recruiting | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced NCT05068102 | Boehringer Ingelheim | Phase 1 |
| Unknown | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice NCT05402059 | MelanomaPRO, Russia | — |
| Unknown | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors NCT05235607 | Sichuan University | Phase 1 |
| Completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors NCT05302921 | Children's National Research Institute | Phase 2 |
| Completed | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) NCT05259696 | Palleon Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression NCT05426317 | University Hospital, Clermont-Ferrand | N/A |
| Terminated | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma NCT04955743 | Yale University | Phase 2 |
| Completed | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morph NCT05116202 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Active Not Recruiting | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population NCT05863052 | University of Oklahoma | — |
| Unknown | To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanom NCT05106023 | Yong Chen | Phase 2 |
| Completed | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma NCT04988841 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US NCT05260684 | Pfizer | — |
| Terminated | Education for Prevention of Melanoma in Hispanic Populations NCT05388851 | Mayo Clinic | Phase 2 |
| Recruiting | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response NCT06116461 | Erasmus Medical Center | Phase 4 |
| Active Not Recruiting | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma NCT04930783 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid NCT05578820 | Gene Surgery LLC | Phase 1 |
| Withdrawn | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors NCT03989050 | University of Cologne | — |
| Unknown | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tum NCT05117138 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma NCT05097378 | CCTU- Cancer Theme | Phase 2 |
| Unknown | Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integra NCT05340543 | Ramsay Générale de Santé | — |
| Active Not Recruiting | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies NCT05013099 | ImaginAb, Inc. | Phase 2 |
| Unknown | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor NCT05156515 | Peking University Cancer Hospital & Institute | N/A |
| Terminated | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed o NCT03978611 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers NCT05031494 | Eucure (Beijing) Biopharma Co., Ltd | Phase 2 |
| Completed | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma NCT04961619 | Novartis Pharmaceuticals | — |
| Unknown | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Cl NCT05180851 | Shanghai Fengxian District Central Hospital | EARLY_Phase 1 |
| Recruiting | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors a NCT04572451 | Yana Najjar | Phase 1 |
| Completed | Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanom NCT02645149 | Melanoma Institute Australia | Phase 2 |
| Completed | Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer NCT05027009 | OHSU Knight Cancer Institute | N/A |